OCA
TNYA icon

Octagon Capital Advisors’s Tenaya Therapeutics TNYA Stock Holding History

Octagon Capital Advisors’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,576,200
Closed -$4.97M – 47
2024
Q3 		$4.97M Hold
2,576,200
– – 0.77% 27
2024
Q2 		$7.99M Sell
2,576,200
-277,800
-10% -$1.15M 1.26% 22
2024
Q1 		$14.9M Buy
+2,854,000
New +$13.7M 1.79% 17

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Octagon Capital Advisors's TNYA Position: Q4 2024 in Review

Octagon Capital Advisors sold out of Tenaya Therapeutics (TNYA) in Q4 2024, closing a stake of 2,576,200 shares — an estimated $4.97M sold.

Octagon Capital Advisors first reported a position in TNYA in Q1 2024 and held it in 3 quarters. The position peaked at $14.9M in Q1 2024. 88 funds tracked by Wall St. Rank hold TNYA as of Q4 2024.

  • Octagon Capital Advisors reported no remaining Tenaya Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 2,576,200 Tenaya Therapeutics shares in Q4 2024, an estimated $4.97M.
  • Octagon Capital Advisors first reported a position in Tenaya Therapeutics in Q1 2024 and held it in 3 quarters.
  • Octagon Capital Advisors's Tenaya Therapeutics position peaked at $14.9M in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q4 2024.

Based on Octagon Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.